H. Spiridonidis

2.7k total citations · 1 hit paper
8 papers, 2.1k citations indexed

About

H. Spiridonidis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry. According to data from OpenAlex, H. Spiridonidis has authored 8 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 1 paper in Organic Chemistry. Recurrent topics in H. Spiridonidis's work include Lung Cancer Treatments and Mutations (5 papers), Neutropenia and Cancer Infections (2 papers) and HER2/EGFR in Cancer Research (2 papers). H. Spiridonidis is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Neutropenia and Cancer Infections (2 papers) and HER2/EGFR in Cancer Research (2 papers). H. Spiridonidis collaborates with scholars based in United States, Australia and Canada. H. Spiridonidis's co-authors include Karen Kelly, Roy S. Herbst, Alan Sandler, Andrea Kay, Mark G. Kris, Steven D. Averbuch, David Cella, Michael Wolf, Diane Prager and Kathy S. Albain and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Asia-Pacific Journal of Clinical Oncology.

In The Last Decade

H. Spiridonidis

8 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 2.1k citations Mark G. Kris, Ronald B. Natale et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Spiridonidis United States	4	1.8k	1.7k	541	288	113	8	2.1k
Daniel T. Milton United States	16	1.9k 1.1×	1.6k 1.0×	587 1.1×	383 1.3×	128 1.1×	27	2.4k
Kristine Pemberton United Kingdom	13	2.0k 1.1×	1.6k 0.9×	490 0.9×	358 1.2×	185 1.6×	14	2.3k
Ira A. Oliff United States	8	1.2k 0.7×	1.3k 0.8×	451 0.8×	226 0.8×	107 0.9×	12	1.7k
Annetta Krebs United States	8	1.9k 1.1×	2.0k 1.2×	723 1.3×	395 1.4×	124 1.1×	8	2.8k
Georgina Speake United Kingdom	11	1.8k 1.0×	1.5k 0.9×	583 1.1×	532 1.8×	135 1.2×	16	2.3k
Toshiyuki Kozuki Japan	25	1.8k 1.0×	2.0k 1.2×	725 1.3×	299 1.0×	137 1.2×	113	3.0k
Adam Płużański Poland	15	1.7k 1.0×	1.6k 1.0×	473 0.9×	319 1.1×	73 0.6×	56	2.1k
Atsushi Horiike Japan	28	1.3k 0.7×	1.3k 0.8×	604 1.1×	391 1.4×	140 1.2×	107	2.1k
Xiuyu Julie Cong United States	13	1.3k 0.7×	1.2k 0.7×	563 1.0×	189 0.7×	70 0.6×	19	1.7k
Jean-Claude Cutz Canada	9	1.8k 1.0×	1.6k 1.0×	815 1.5×	519 1.8×	131 1.2×	12	2.4k

Countries citing papers authored by H. Spiridonidis

Since Specialization

Citations

This map shows the geographic impact of H. Spiridonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Spiridonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Spiridonidis more than expected).

Fields of papers citing papers by H. Spiridonidis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Spiridonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Spiridonidis. The network helps show where H. Spiridonidis may publish in the future.

Co-authorship network of co-authors of H. Spiridonidis

This figure shows the co-authorship network connecting the top 25 collaborators of H. Spiridonidis. A scholar is included among the top collaborators of H. Spiridonidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Spiridonidis. H. Spiridonidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Kris, Mark G., Ronald B. Natale, Roy S. Herbst, et al.. (2017). Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer. 3 indexed citations

2.

Souza, Paul L. de, et al.. (2010). A phase II trial of weekly i.v. KW‐2170 in advanced castrate‐resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology. 6(4). 292–297. 4 indexed citations

3.

Spiridonidis, H., et al.. (2004). Symptomatic response to a non-platinum doublet in performance status 2 (PS 2) patients (pts) with non-small lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7303–7303. 3 indexed citations

4.

Spiridonidis, H., et al.. (2004). Symptomatic response to a non-platinum doublet in performance status 2 (PS 2) patients (pts) with non-small lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7303–7303. 1 indexed citations

5.

Laufman, Leslie R., et al.. (2004). Smoking status affects chemotherapy-induced neutropenia. Journal of Clinical Oncology. 22(14_suppl). 8097–8097. 2 indexed citations

6.

Laufman, Leslie R., et al.. (2004). Smoking status affects chemotherapy-induced neutropenia. Journal of Clinical Oncology. 22(14_suppl). 8097–8097. 1 indexed citations

7.

Kris, Mark G., Ronald B. Natale, Roy S. Herbst, et al.. (2003). Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer. JAMA. 290(16). 2149–2149. 2119 indexed citations breakdown →

8.

Lynch, Timothy, et al.. (2003). Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact